Moneycontrol PRO

you are here: HomeNewsBusinessCompaniesCipla tells Merck your anti-AIDS drug too costly in India

SHOW NAMES

Trending Topics

Sensex Live Advance Agrolife IPO US Dollar Index Jaro Institute IPO Anand Rathi IPO

business

Cipla tells Merck your anti-AIDS drug too costly in India

Domestic pharma giant Cipla has taken the route of applying for a "voluntary license" for Merck's HIV Isentress (a generic raltegravir) saying it is not reaching needy patients in India and is prices exorbitantly.

first published: Apr 4, 2011 12:50 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347